Prevalence of the molecular marker of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in Benin seven years after the change of malaria treatment policy

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Ogouyèmi Hounto, Aurore ^a   Ndam, Nicaise Tuikue ^b   Kinde Gazard, Dorothée ^a   D'Almeida, Sitou ^a   Koussihoude, Lucette ^a   Ollo, Elvire ^a   Azagnandji, Carmine ^a   Bello, Mourchidath ^a   Chippaux, Jean Phillipe ^b   Massougbodji, Achille ^a  

^a UNIVERSITY OF ABOMEY CALAVI   (Benin)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

Chloroquine; P. falciparum; Prevalence mutation; Sulphadoxine pyrimethamine

Indexed keywords

BIOLOGICAL MARKER; CHLOROQUINE; PYRIMETHAMINE PLUS SULFADOXINE;

ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CODON; DISEASE TRANSMISSION; FEMALE; GENE MUTATION; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PARASITE; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD;

ADOLESCENT; ANTIMALARIALS; BENIN; BLOOD; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DNA, PROTOZOAN; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; GENETIC MARKERS; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MUTATION RATE; PLASMODIUM FALCIPARUM; POINT MUTATION; PREVALENCE; PROTOZOAN PROTEINS; PYRIMETHAMINE; SULFADOXINE;

EID: 84876791857     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-147     Document Type: Article

References (40)

1. Organisation mondiale de la Santé Surveillance de la résistance aux antipaludiques. Rapport d'une consultation de l'OMS, Genève, Suisse, 3-5 décembre 2001 WHO/CDS/CSR/EPH/2002.17/WHO/CDS/ RBM 2002 39 http://whqlibdoc.who.int/hq/2002/who-cds-csr-eph-2002.17-fre.pdf 11931579
2. Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Aubouy A, Fievet N, Bertin G, Sagbo JC, Kossou H, Kinde-Gazard D, Kiniffo R, Massougbodji A, Deloron P, Trop Med Int Health 2007 12 886 894 10.1111/j.1365-3156.2007. 01859.x 17596256 (Pubitemid 46998287)
3. Organisation mondiale de la Santé Evaluation et surveillance de l'efficacité des antipaludiques dans le traitement du paludisme à Plasmodium falciparum non compliqué OMS, Genève: Document WHO/RBM 2003 50 67 21440569
4. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ, Dorsey G, AmJTrop Med Hyg 2003 69 247 252
5. Molecular markers for failure of sulfadoxine- pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, J Infect Dis 2002 185 380 388 10.1086/338566 11807721 (Pubitemid 34107252)
6. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naudé B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE, Mol Cell 2000 6 861 871 10.1016/S1097-2765(05)00077-8 11090624
7. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Sidhu AB, Verdier-Pinard D, Fidock DA, Science 2002 298 210 213 10.1126/science.1074045 12364805
8. Chloroquine-resistant malaria. Wellems TE, Plowe CV, J Infect Dis 2001 184 770 776 10.1086/322858 11517439 (Pubitemid 32826429)
9. Prevalence of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from southern Mauritania. Eberl KJ, Jelinek T, Aida AO, Peyerl-Hoffmann G, Heuschkel C, El Valy AO, Christophe EM, Trop Med Int Health 2001 6 756 760 10.1046/j.1365-3156. 2001.00791.x 11679122 (Pubitemid 32989627)
10. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimdé AA, Kouriba B, Taylor TE, Plowe CV, J Infect Dis 2003 187 1870 1875 10.1086/375419 12792863 (Pubitemid 36724485)
11. Return of chloroquine antimalarialefficacy in Malawi. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV, N Engl J Med 2006 355 1959 1966 10.1056/NEJMoa062032 17093247 (Pubitemid 44708015)
12. Extended high efficacy of the combination sulphadoxine-pyrimethamine with artesunate in children with uncomplicated falciparum malaria on the Benin coast. Nahum A, Erhart A, Ahounou D, Bonou D, Van Overmeir C, Menten J, Akogbeto M, Coosemans M, Massougbodji A, D'Alessandro U, West Africa. Malar J 2009 8 37
13. Molecular markers of resistance to sulphadoxine pyrimethamine during intermittent preventive treatment of pregnant women in Benin. Bertin G, Briand V, Bonaventure D, Carrieu A, Massougbodji A, Cot M, Deloron P, Malar J 2011 10 196 10.1186/1475-2875-10-196 21767415
14. Programme national de lutte contre le paludisme, Plan stratégique de lutte contre le paludisme au Benin 2006-2010 http://www.rbm.who.int/ countryaction/nsp/benin.pdf 16614329
15. Severe falciparum malaria. WHO/Communicable diseases cluster, Trans R Soc Trop Med Hyg 2000 94 0S1 S90
16. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE, Am J TropMed Hyg 1995 52 565 568
17. A molecular marker for chloroquine-resistant falciparum malaria. Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, N Engl J Med 2001 344 257 263 10.1056/NEJM200101253440403 11172152 (Pubitemid 32108530)
18. Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy. Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP, Vestergaard LS, Theander TG, Lemnge MM, Bygbjerg IC, Alifrangis M, Am J Trop Med Hyg 2011 85 979 983 10.4269/ajtmh.2011.11-0071 22144430
19. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of Northern Tanzania. Pearce R, Drakeley C, Chandramohan D, Mosha F, Roper C, Antimicrob Agents Chemother 2003 47 1347 1354 10.1128/AAC.47.4.1347- 1354.2003 12654669 (Pubitemid 36368596)
20. Dramatic decrease in malaria transmission after large-scale indoor residual spraying with bendiocarb in Benin, an area of high resistance of Anopheles gambiae to pyrethroids. Akogbeto M, Padonou GG, Bankole HS, Kinde Gazard D, Gbedjissi GL, Am J Trop Med Hyg 2011 85 586 593 10.4269/ajtmh.2011.10- 0668 21976555
21. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carterand D, Doumbo OK, J Infect Dis 1997 176 1590 1596 10.1086/514159 9395372 (Pubitemid 27518161)
22. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Diourte Y, Djimde A, Doumbo OK, Sagara I, Coulibaly Y, Dicko D, Diallo M, Diakite M, Cortese JF, Plowe CV, Am J Trop Med Hyg 1999 60 475 478 10466980 (Pubitemid 29162134)
23. Rapid selection of Plasmodium falcipavum dihydrofolate reductase mutants by pyrimethamine prophylaxis. Doumbo OK, Kayentao K, Djimde A, Cortese JF, Diourte Y, Konaré A, Kublin JG, Plowe CV, J Infect Dis 2000 182 993 996 10.1086/315787 10950805
24. Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia. Mula P, Fernández-Martínez A, de Lucio A, Ramos JM, Reyes F, González V, Benito A, Berzosa P, Malar J 2011 10 214 10.1186/1475-2875-10-214 21810256
25. In vivo chloroquine resistance and prevalence of the pfcrt codon 76 mutation in Plasmodium falciparum isolates from the Republic of Congo. Mayengue PI, Ndounga M, Davy MM, Tandou N, Ntoumi F, Acta Trop 2005 95 219 225 10.1016/j.actatropica.2005.06.001 16002038 (Pubitemid 41207285)
26. Distribution of drug resistance genotypes in Plasmodium falciparum in an area of limited parasite diversity in Saudi Arabia. Bin Dajem SM, Al-Farsi HM, Al-Hashami ZS, Al-Sheikh AA, Al-Qahtani A, Babiker HA, AmJTrop Med Hyg 2012 86 782 788 10.4269/ajtmh.2012.11-0520
27. High Resistance of Plasmodium falciparum to Sulphadoxine/Pyrimethamine in Northern Tanzania and the emergence of dhps resistance mutation at codon 581. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, Mosha JF, Joho A, Mandia V, Mrema H, Mapunda E, Savael Z, Lemnge M, Mosha FW, Greenwood B, Roper C, Chandramohan D, PLoS One 2009 4 4569 10.1371/journal.pone.0004569 19238219
28. High prevalence of sulphadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at the time of introduction of intermittent preventive treatment with sulphadoxine/pyrimethamine in Gabon. Bouyou-Akotet MK, Mawili-Mboumba DP, Tchantchou TD, Kombila M, J Antimicrob Chemother 2010 65 438 441 10.1093/jac/dkp467 20053688
29. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Nzila A, Mberu J, Sulo H, Dayo PA, Winstanley CH, Sibley W, Watkins M, Antimicrob Agents Chemother 2000 44 991 996 10.1128/AAC.44.4.991-996.2000 10722502 (Pubitemid 30165281)
30. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Sibley CHJE, Hyde PFG, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WA, Nzila AM, Trends Parasitol 2001 17 582 588 10.1016/S1471-4922(01) 02085-2 11756042 (Pubitemid 34088118)
31. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum dhfr mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. Tinto H, Ouedraogo JB, Zongo I, Van Overmeir C, Van Marck E, Guiguemdé TR, D'alessandro U, AmJTrop Med Hyg 2007 76 608 613 (Pubitemid 351627694)
32. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Mockenhaupt FP, Teun BJ, Eggelte TA, Schreiber J, Ehrhardt S, Wassilew N, Otchwemah RN, Sauerwein RW, Bienzle U, Trop Med Int Health 2005 10 901 908 10.1111/j.1365-3156.2005.01471.x 16135198 (Pubitemid 41291231)
33. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Frosch AEP, Venkatesan M, Laufer MK, Malar J 2011 10 116 10.1186/1475-2875-10-116 21554692
34. Evolution de la chimiosensibilité de Plasmodium falciparum à la chloroquine et à la méfloquine au Benin entre 1980 et 1989. Chippaux JP, Massougbodji A, Akogbeto M, Josse R, Zohoun T, Sadeler BC, Bull Soc Path Exot 1990 83 320 329 (Pubitemid 20323585)
35. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Ginsburg H, Famin O, Zhang J, Krugliak M, Biochem Pharmacol 1998 56 1305 1313 10.1016/S0006-2952(98)00184-1 9825729 (Pubitemid 28511267)
36. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Björkman A, Infect Gen Evol 2006 6 309 314 10.1016/j.meegid.2005.09.001 (Pubitemid 43785813)
37. Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in China. Zhang GQ, Guan YY, Zheng B, Wu S, Tang LH, Trop Med Int Health 2009 14 1266 1271 10.1111/j.1365-3156.2009.02342.x 19772548
38. Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-westernTanzania. Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, Kironde F, Swedberg G, Malar J 2012 11 58 10.1186/1475-2875-11-58 22369089
39. Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. Raman J, Mauff K, Mulanga P, Mussa A, Maharaj R, Barnes K, PLoS One 2011 6 8
40. A community-randomised evaluation of the effect of IPTi on anti-malarial drug resistance in southern Tanzania. Pearce RJ, Ord R, Kaur H, Lupala C, Schellenberg J, Shirima K, Manzi F, Alonso P, Tanner M, Mshinda H, Roper C, Schellenberg D, J Infect Dis 2013 207 848 859 10.1093/infdis/jis742 23225897